Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema

With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.